Cognitive function and adaptive skills after a one-year trial of cannabidiol (CBD) in a pediatric sample with treatment-resistant epilepsy.

摘要: Abstract Objective Cannabidiol (CBD) is a nonpsychoactive derivative of cannabis. Studies indicate that it safe and effective in treating certain types epilepsy. The present study examined the presence adverse or beneficial cognitive functional adaptive effects associated with CBD treatment children, adolescents, teenagers treatment-resistant epilepsy (TRE) as part an ongoing prospective, open-label safety study. Methods Participants (N = 38) between age 3 19 years TRE were enrolled pharmaceutical formulation (Epidiolex®; GW Research Ltd.) add-on treatment. In addition to baseline physical, neurological, laboratory testing, assessment was completed prior initiating after one year, both using NIH Toolbox Cognition Battery (NIHTB-CB). Many participants unable complete NIHTB-CB because magnitude their impairment (n = 24), these cases, participant's caregiver asked Adaptive Behavior Assessment System – Second Edition (ABAS-II) measure skills. Results There no statistically significant changes function, measured by NIHTB-CB, those who able such but there nonsignificant trend toward improvement some domains. For formal standardized testing impairment, skills, ABAS-II, unchanged one-year trial CBD. Significance Our findings suggest CBD, drug for pediatric sample, does not appear cause (AEs) involving cognition function over year